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Fulminant hepatitis is a serious, life-threatening disorder and
is associated with inflammatory cytokines produced by Kupffer
cells. However, a number of clinical trials for the treatment of
fulminant hepatitis did not show enough substantial ben-
efits. Since NF-κB is a key mediator of inflammatory response
in Kupffer cells, NF-κB decoy would be an attractive candi-
date for the treatment of fulminant hepatitis. Recently,
Opanasopit et al. revealed that fucosylated protein is prefer-
entially taken up by Kupffer cells via a fucose receptor (Fuc-
R). Therefore, the fucosylation to NF-κB decoy carrier is one of
the prominent approaches for Kupffer cell-selective delivery.
We recently reported that thioalkylated mannose-modified star
burst polyamidoamine (PAMAM) dendrimer/α-cyclodextrin con-
jugates (Man-S-α-CDE (G3)) has the potential for a novel antigen
presenting cell-selective siRNA carrier [1]. However, there is no
report on fucose-appended α-CDE as a Kupffer cell-selective
NF-κB decoy carrier. Therefore, in the present study, we newly
synthesized fucosyl-oxypropyl-thio-propionylated α-CDE(Fuc-
S-α-CDE (G2) (Fig. 1A)) and evaluated the potential of Fuc-S-
α-CDE (G2)/NF-κB decoycomplex for the treatment of fulminant
hepatitis [2].
Fuc-S-α-CDE (G2, average degree of substitution of fucose
(DSF) 2)/NF-κB decoy complex significantly suppressed nitric
oxide and tumor necrosis factor-α (TNF-α) production from li-
popolysaccharide (LPS)-simulated NR8383 cells, a rat alveolar
macrophage cell line, by adequate physicochemical proper-
ties and fucose receptor-mediated cellular uptake. Intravenous
injection of Fuc-S-α-CDE (G2, DSF2)/NF-κB decoy complex
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extended the survival of LPS-induced fulminant hepatitis model
mice, compared to those of NF-κB decoy alone and jetPEI™-
Macrophage/NF-κB decoy complex (Fig. 1B). In addition, Fuc-
S-α-CDE (G2, DSF2)/NF-κB decoy complex administered
intravenously highly accumulated in the liver, compared to
naked NF-κB decoy alone. Furthermore, the liver accumula-
tion of Fuc-S-α-CDE (G2, DSF2)/NF-κB decoy complex was
inhibited by the pretreatment with GdCl3, a specific inhibitor
of Kupffer cell uptake. Also, the serum aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT) and TNF-α levels
in LPS-induced fulminant hepatitis model mice were signifi-
cantly attenuated by the treatment with Fuc-S-α-CDE (G2, DSF2)/
NF-κB decoy complex, compared with naked NF-κB decoy alone.
Taken together, these results suggest that Fuc-S-α-CDE (G2,
DSF2) has the potential for a novel Kupffer cell-selective NF-
κB decoy carrier for the treatment of LPS-induced fulminant
hepatitis in mice.
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Fig. 1 – Chemical structure of Fuc-S-α-CDE (G2)(A) and effects of Fuc-S-α-CDE (G2, DSF2)/NF-κB decoy complex on survival
curve of fulminant hepatitis mice induced by LPS. Each line represents the survival of 4–10 mice. *P < 0.05 versus LPS alone
(B).
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